{"transactions":[{"id":722912,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T23:00:13.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":37.34,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-291056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000119312526291056/ownership.xml","form_type":"4"}},{"id":757233,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-01T20:10:43.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":123600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the \"2021 Plan\")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date."}],"balance_after":123600,"derivative":{"exercise_price":0.9515,"expiration_date":"2036-05-27","underlying":"Class A Common Stock","underlying_shares":123600},"source":{"system":"sec-edgar","filing":"0001864485-26-000003","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000186448526000003/ownership.xml","form_type":"4"}},{"id":1013281,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-27T23:29:24.000Z","date":"2025-10-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over a three-year period, with one-third of the shares subject to the option vesting on October 23, 2026, and one thirty-sixth of the shares subject to the option vesting each month thereafter, subject to the Reporting Person's continuous service with the Company through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.09,"expiration_date":"2035-10-22","underlying":"Class A Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001864485-25-000005","document":"form4-10272025_111020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000186448525000005/form4-10272025_111020.xml","form_type":"4"}},{"id":1062000,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-19T20:41:44.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000300","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000161071725000300/form4.xml","form_type":"4"}},{"id":1105151,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:38:23.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":16623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":16623,"derivative":{"exercise_price":10.24,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":16623},"source":{"system":"sec-edgar","filing":"0000950170-25-088616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000095017025088616/ownership.xml","form_type":"4"}},{"id":1105150,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T21:41:36.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000247","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000161071725000247/form4.xml","form_type":"4"}},{"id":1488588,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:30:32.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the \"Vesting Commencement Date\") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":23742,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001610717-24-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000161071724000302/form4.xml","form_type":"4"}},{"id":1744207,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T23:44:01.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":25000,"derivative":{"exercise_price":15,"expiration_date":"2033-11-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-23-000344","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000161071723000344/form4.xml","form_type":"4"}},{"id":1824956,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-21T21:02:57.000Z","date":"2023-07-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.72,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-043129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000120919123043129/doc4.xml","form_type":"4"}},{"id":2224327,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T21:35:51.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.54,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000120919122038729/doc4.xml","form_type":"4"}},{"id":2653811,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":34496,"kind":"person","name":"Bassan Abraham","position":1,"cik":"0001864485","reported_name":"Bassan Abraham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-29T00:00:20.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 24, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":40000,"derivative":{"exercise_price":17,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-026339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864485/000089924321026339/doc4.xml","form_type":"4"}}]}